Neonatal Med.  2020 Aug;27(3):99-104. 10.5385/nm.2020.27.3.99.

Comparison of Respiratory Outcomes between Less Invasive Surfactant Administration and the IntubationSurfactant-Extubation Technique in Premature Infants with Respiratory Distress Syndrome

• Kim HS
• Kim HH
• Yang M
• Han YS
• Sung SI
• Ahn SY
• Chang YS
• Park WS

• KMID: 2505659
• DOI: http://doi.org/10.5385/nm.2020.27.3.99

Abstract

Purpose
To compare respiratory outcomes between less invasive surfactant admi nistration (LISA) and the intubation-surfactant-extubation (INSURE) technique in premature infants with respiratory distress syndrome (RDS).
Methods
We performed a retrospective medical chart review for 75 premature in fants who were born at a gestational age (GA) of ≤34 weeks (between January 2017 and December 2019) and developed RDS after birth. Data on the demographic and outcome variables, including respiratory outcomes, were collected and compared between the infants who received LISA and those who received INSURE as a rescue therapy for RDS.
Results
No signifcant differences in GA, birth weight, and other demographic characteristics were found between the LISA and INSURE groups (GA: 28.7 weeks vs. 28.8 weeks, P=0.449; birth weight: 1,236 g vs. 1,124 g, P=0.714). At the delivery room, although the infants showed no significant difference in positive pressure ventilation rate after birth, the LISA group showed a higher rate of continuous positive airway pressure application than the INSURE group. The infants in the LISA group presented a higher risk of requiring multiple doses of surfactant for RDS than the infants in the INSURE group (57% vs. 17.5%, P=0.001). However, the duration of invasive and/ or noninvasive respiratory support and incidence of bronchopulmonary dysplasia showed no signifciant difference between the two groups.
Conclusion
In the present study, no significant differences in the incidence of inhospital respiratory outcomes such as bronchopulmonary dysplasia were found between the LISA and INSURE groups. These results suggest that LISA can be an alternative therapeutic option for treating RDS to avoid intubation and mechanica ventilation in premature infants.

Keyword

Surface-active agents; Respiratory distress syndrome in premature infants

Reference

1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001; 163:1723–9.

2. Bancalari E, del Moral T. Bronchopulmonary dysplasia and surfactant. Biol Neonate. 2001; 80 Suppl 1:7–13.

3. Brew N, Hooper SB, Allison BJ, Wallace MJ, Harding R. Injury and repair in the very immature lung following brief mechanical ventilation. Am J Physiol Lung Cell Mol Physiol. 2011; 301:L917–26.

4. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. 2007; 4:CD003063.

5. Aguar M, Vento M, Dargaville PA. Minimally invasive surfactant therapy: an update. NeoReviews. 2014; 15:e275–85.

6. Isayama T, Iwami H, McDonald S, Beyene J. Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants: a systematic review and meta-analysis. JAMA. 2016; 316:611–24.

7. Fischer HS, Buhrer C. Avoiding endotracheal ventilation to prevent bronchopulmonary dysplasia: a meta-analysis. Pediatrics. 2013; 132:e1351–60.

8. Schmolzer GM, Kumar M, Pichler G, Aziz K, O'Reilly M, Cheung PY. Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ. 2013; 347:f5980.

9. Aly H, Milner JD, Patel K, El-Mohandes AA. Does the experience with the use of nasal continuous positive airway pressure improve over time in extremely low birth weight infants? Pediatrics. 2004; 114:697–702.

10. Subramaniam P, Ho JJ, Davis PG. Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev. 2016; 6:CD001243.

11. Finer N. To intubate or not, that is the question: continuous positive airway pressure versus surfactant and extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2006; 91:F392–4.

12. Berneau P, Nguyen Phuc Thu T, Pladys P, Beuchee A. Impact of surfactant administration through a thin catheter in the delivery room: a quality control chart analysis coupled with a propensity score matched cohort study in preterm infants. PLoS One. 2018; 13:e0208252.

13. More K, Sakhuja P, Shah PS. Minimally invasive surfactant administration in preterm infants: a meta-narrative review. JAMA Pediatr. 2014; 168:901–8.

14. Herting E. Less invasive surfactant administration (LISA): ways to deliver surfactant in spontaneously breathing infants. Early Hum Dev. 2013; 89:875–80.

15. Halim A, Shirazi H, Riaz S, Gul SS, Ali W. Less invasive surfactant administration in preterm infants with respiratory distress syndrome. J Coll Physicians Surg Pak. 2019; 29:226–330.

16. Gregory KE, Deforge CE, Natale KM, Phillips M, Van Marter LJ. Necrotizing enterocolitis in the premature infant: neonatal nursing assessment, disease pathogenesis, and clinical presentation. Adv Neonatal Care. 2011; 11:155–64.

17. Roggini M, Pepino D, D'Avanzo M, Andreoli GM, Ceccanti S, Capocaccia P. Respiratory distress in newborn: evaluation of chest X-rays. Minerva Pediatr. 2010; 62:217–9.

18. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2001; 2:CD000510.

19. Verder H, Albertsen P, Ebbesen F, Greisen G, Robertson B, Bertelsen A, et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. Pediatrics. 1999; 103:E24.

20. Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, Lundstrom K, et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group. N Engl J Med. 1994; 331:1051–5.

21. Dargaville PA, Aiyappan A, Cornelius A, Williams C, De Paoli AG. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch Dis Child Fetal Neonatal Ed. 2011; 96:F243–8.

22. Yang G, Hei M, Xue Z, Zhao Y, Zhang X, Wang C. Effects of less invasive surfactant administration (LISA) via a gastric tube on the treatment of respiratory distress syndrome in premature infants aged 32 to 36 weeks. Medicine (Baltimore). 2020; 99:e19216.

23. Kribs A, Hartel C, Kattner E, Vochem M, Kuster H, Moller J, et al. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin Padiatr. 2010; 222:13–7.

24. Herting E, Hartel C, Gopel W. Less invasive surfactant administration (LISA): chances and limitations. Arch Dis Child Fetal Neonatal Ed. 2019; 104:F655–9.

25. Niemarkt HJ, Kuypers E, Jellema R, Ophelders D, Hutten M, Nikiforou M, et al. Effects of less-invasive surfactant administration on oxygenation, pulmonary surfactant distribution, and lung compliance in spontaneously breathing preterm lambs. Pediatr Res. 2014; 76:166–70.

26. Hartel C, Paul P, Hanke K, Humberg A, Kribs A, Mehler K, et al. Less invasive surfactant administration and complications of preterm birth. Sci Rep. 2018; 8:8333.